Karyopharms Xpovio In Multiple Myeloma Priced At $22000 Per FourWeek Cycle
Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle
15:13 EDT 3 Jul 2019 |
SCRIP
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing...
More From BioPortfolio on "Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle"